Drug Discovery
ByStrategic Industry Analysis: What the Biggest Biopharma Deals of 2025 Reveal About the Future of Drug Innovation
The global biopharmaceutical industry experienced a powerful wave of strategic dealmaking in 2025 as major pharmaceutical companies accelerated…
EU Regulators Back CAMCEVI: A Key Step Toward Expanding Prostate Cancer Treatment Options
Foresee Pharmaceuticals has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of…
Can aTyr Pharma’s Upcoming FDA Meeting Accelerate the Path to Approval for Efzofitimod?
aTyr Pharma has reported its fourth-quarter and full-year 2025 financial results while outlining a pivotal regulatory milestone ahead:…
Did the Zealand Pharma–Roche Obesity Partnership Hit an Early Roadblock?
A closely watched obesity drug collaboration between Zealand Pharma and Roche has encountered an unexpected setback after early…
Can Novartis AG’s $3 Billion AI-Driven Oncology Bet Redefine Precision Breast Cancer Treatment and Accelerate Next-Gen Drug Discovery?
Key Highlights: AI-Led Drug Discovery Accelerates Target Identification and ValidationNovartis AG’s acquisition of SNV4818 from Synnovation Therapeutics, Inc.…
How Will Emerging Drug Pricing Policies Reshape the Global Biopharma Industry in the Near and Long Term?
The global biopharmaceutical industry is entering a new policy-driven era as governments intensify efforts to control drug costs,…
